Ceeto Capital Group LLC Purchases 500 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Ceeto Capital Group LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,200 shares of the biopharmaceutical company’s stock after acquiring an additional 500 shares during the quarter. Ceeto Capital Group LLC’s holdings in Gilead Sciences were worth $1,187,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Private Wealth Management Group LLC acquired a new position in Gilead Sciences during the 4th quarter valued at approximately $29,000. Palisade Asset Management LLC acquired a new position in Gilead Sciences during the 1st quarter valued at approximately $29,000. Sachetta LLC acquired a new position in Gilead Sciences during the 4th quarter valued at approximately $30,000. Rakuten Securities Inc. acquired a new stake in shares of Gilead Sciences in the fourth quarter worth $33,000. Finally, Gladius Capital Management LP acquired a new stake in shares of Gilead Sciences in the fourth quarter worth $34,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

GILD traded up $0.50 during midday trading on Friday, hitting $77.01. 7,453,639 shares of the company traded hands, compared to its average volume of 6,033,727. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $95.94 billion, a price-to-earnings ratio of 213.92, a PEG ratio of 3.28 and a beta of 0.18. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $87.86. The business has a 50 day simple moving average of $67.79 and a two-hundred day simple moving average of $70.98.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company’s revenue was up 5.3% compared to the same quarter last year. During the same period last year, the firm posted $1.37 earnings per share. On average, equities analysts forecast that Gilead Sciences, Inc. will post 3.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on GILD shares. UBS Group cut their price objective on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Oppenheimer reiterated an “outperform” rating and issued a $105.00 price objective on shares of Gilead Sciences in a research note on Friday, April 19th. Barclays cut their price objective on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a research note on Monday, April 29th. TD Cowen cut their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Friday, April 26th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $74.00 price objective on shares of Gilead Sciences in a research note on Monday, July 1st. Twelve analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Hold” and an average target price of $81.81.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.